Compositions, methods and kits relating to Her-2 cleavage
US8088737B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 2, 2004 |
| Grant date | Jan 3, 2012 |
| Priority date | — |
| Expiry date | Jul 15, 2027 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compositions, methods and kits based on the ADAM-mediated cleavage of Her-2. The present invention also relates to treatments for cancer, and in particular, breast cancer, by modulating the ADAM-mediated cleavage of Her-2. Further, the invention relates to compositions, methods and kits based on the surprising synergistic effect between inhibition of Her-2 cleavage by an ADAM and certain cytostatic (e.g., Herceptin) and cytotoxic (e.g., Taxol) compounds in, among other things, inhibiting tumor cell proliferation and inducing cell death. Additionally, the invention relates to novel variants of ADAM15, designated ADAM15 variant 1 and ADAM15 variant 2, now identified and isolated.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.